Identification of mutations in the epidermal growth factor receptor (EGFR), K-ras gene, and most recently the echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase (EML4-ALK) fusion gene have had a decisive impact on the treatment of NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.